Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652455 · ClinicalTrials.gov registry record · Early Phase 1
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT02652455 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 11 participants.
The verdict
NCT02652455, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this Pilot Study is to investigate the safety, side effects, and benefits of tumor- infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases. The primary endpoints of this pilot trial will be the safety and feasibility of the treatment regimens.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Nivolumab
- PROCEDURE Surgery to Remove Tumor for Growth of TIL
- DRUG CD137
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-03-08 |
| Est. Completion | 2020-08-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652455
The ClinicalTrials.gov registry entry for NCT02652455 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02652455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02652455 about?
NCT02652455 is a clinical study titled "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma". The purpose of this Pilot Study is to investigate the safety, side effects, and benefits of tumor- infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infect...
What is the current status of trial NCT02652455?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2016-03-08. Estimated completion is 2020-08-30.
What interventions are being tested in trial NCT02652455?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Nivolumab (DRUG), Surgery to Remove Tumor for Growth of TIL (PROCEDURE), CD137 (DRUG).
Who is sponsoring clinical trial NCT02652455?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.